Uncategorized

Crecen las emisiones de un gas con un efecto invernadero 24.300 veces más potente que el del dióxido de carbono

Para alcanzar el objetivo al que aspira el Acuerdo de París sobre el cambio climático global (limitar el aumento de la temperatura media global en superficie de la Tierra a 1,5 grados centígrados por encima de la imperante poco antes del inicio de la Revolución Industrial …

Crecen las emisiones de un gas con un efecto invernadero 24.300 veces más potente que el del dióxido de carbono Read More »

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

SimBioSys announced a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development Read More »

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Bristol Myers Squibb announced that the European Commission has expanded approval of Reblozyl® to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes.

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Read More »

RemeGen’s Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren’s Syndrome

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.

RemeGen’s Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren’s Syndrome Read More »

Scroll to Top